Cancers,
Journal Year:
2022,
Volume and Issue:
14(8), P. 2018 - 2018
Published: April 16, 2022
Hepatocellular
carcinoma
(HCC)
is
the
most
frequent
primary
liver
tumor.
As
a
result
of
advanced
disease
being
often
present
at
diagnosis,
only
small
percentage
patients
are
amenable
to
curative-intent
treatment
options
such
as
surgical
resection
and
transplantation.
Systemic
therapy
consisting
tyrosine
kinase
inhibitors
sorafenib
had
been
used
for
over
decade
with
limited
efficacy.
More
recently,
immune
checkpoint
has
revolutionized
landscape
various
malignant
tumors.
With
this
shifting
paradigm,
recent
data
have
demonstrated
encouraging
outcomes
among
HCC.
In
particular,
several
trials
investigated
safety
efficacy
(ICI)
either
monotherapy
or
in
form
combined
treatments.
We
sought
provide
an
overview
clinical
HCC
well
highlight
predictors
response
immune-related
adverse
events
review
evidence
on
perioperative
administration
ICI
resectable
Cancer Cell International,
Journal Year:
2023,
Volume and Issue:
23(1)
Published: April 10, 2023
Abstract
Cancer
is
still
the
leading
cause
of
death
globally.
The
approval
therapeutic
use
monoclonal
antibodies
against
immune
checkpoint
molecules,
notably
those
that
target
proteins
PD-1
and
PD-L1,
has
changed
landscape
cancer
treatment.
In
particular,
first-line
PD-1/PD-L1
inhibitor
drugs
are
increasingly
common
for
treatment
metastatic
cancer,
significantly
prolonging
patient
survival.
Despite
benefits
brought
by
inhibitors
(ICIs)-based
therapy,
majority
patients
had
their
diseases
worsen
following
a
promising
initial
response.
To
increase
effectiveness
ICIs
advance
our
understanding
mechanisms
causing
resistance,
it
crucial
to
find
new,
effective,
tolerable
combination
treatments.
this
article,
we
addressed
potential
solid
tumors
offer
some
insight
into
molecular
pathways
behind
resistance
ICIs.
We
also
discuss
cutting-edge
methods
reactivating
T-cell
responsiveness
after
been
established.
Cellular and Molecular Immunology,
Journal Year:
2024,
Volume and Issue:
21(12), P. 1354 - 1375
Published: Oct. 15, 2024
Glioblastoma
(GBM)
is
an
aggressive
and
lethal
type
of
brain
tumor
in
human
adults.
The
standard
care
offers
minimal
clinical
benefit,
most
GBM
patients
experience
recurrence
after
treatment.
In
recent
years,
significant
advancements
have
been
made
the
development
novel
immunotherapies
or
other
therapeutic
strategies
that
can
overcome
immunotherapy
resistance
many
advanced
cancers.
However,
benefit
immune-based
treatments
limited
because
unique
immune
profiles,
cell
heterogeneity,
immunosuppressive
microenvironment.
this
review,
we
present
a
detailed
overview
current
immunotherapeutic
discuss
challenges
potential
molecular
mechanisms
underlying
GBM.
Furthermore,
provide
in-depth
discussion
regarding
GBM,
which
will
likely
require
combination
therapies.
Annals of Translational Medicine,
Journal Year:
2023,
Volume and Issue:
11(10), P. 354 - 354
Published: Aug. 1, 2023
Background:
The
introduction
of
immunotherapy
in
the
treatment
non-small
cell
lung
cancer
(NSCLC)
has
resulted
a
radical
change
patients’
responses
and
survival
rates.
increased
percentage
long
survivors,
improved
toxicity
profiles
compared
to
chemotherapy,
possible
applications
for
different
NSCLC
scenarios,
have
led
immune
checkpoint
inhibitors
(ICIs)
becoming
cornerstone
treatment.
Therefore,
objective
this
review
is
describe
current
future
perspectives
Methods:
A
systematic
according
PRISMA
criteria
been
performed
based
on
clinical
trials
with
from
start
these
treatments
until
June
2022.
Results:
use
ICIs
widespread
across
both
first-
second-line
anti-PD-1,
anti-PD-L1,
anti-CTLA-4
drugs.
New
indications
focused
adjuvant
(atezolizumab)
neoadjuvant
(nivolumab),
now
present
all
stages
Given
promising
results
seen
trials,
new
[anti-
lymphocyte
activation
gene-3
(LAG-3)
or
IDO1]
currently
under
development,
will
soon
be
used
as
standard
NSCLC.
Conclusions:
Immunotherapy
mainstay
stages,
including
adjuvant,
advanced
tumors.
development
molecules
revolutionize
coming
years.
Cureus,
Journal Year:
2023,
Volume and Issue:
unknown
Published: June 6, 2023
Bladder
cancer
is
a
prevalent
disease,
and
treatment
options
for
advanced
bladder
remain
limited.
However,
immune
checkpoint
inhibitors
(ICIs)
targeting
cytotoxic
T-lymphocyte-associated
antigen-4
(CTLA-4)
programmed
cell
death-1
(PD-1)
have
shown
promise
in
treating
cancer.
These
drugs
work
by
blocking
receptors
ligands,
disrupting
signaling,
allowing
T
cells
to
recognize
attack
cells.
ICIs
been
found
be
effective
cancer,
especially
cases
of
metastatic
urothelial
carcinoma
(UC)
that
progressed
after
chemotherapy.
Furthermore,
combination
therapy
with
chemotherapy
or
radiation
has
While
there
are
challenges
associated
ICIs,
including
adverse
effects,
immune-related
events,
lack
efficacy
some
patients,
they
promising
option
treatment,
where
other
failed.
This
review
paper
focuses
on
the
current
role,
challenges,
future
trends
immunotherapy
management
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Feb. 13, 2024
T
cell
senescence
is
an
indication
of
dysfunction.
The
ability
senescent
cells
to
respond
cognate
antigens
reduced
and
they
are
in
the
late
stage
differentiation
proliferation;
therefore,
cannot
recognize
eliminate
tumor
a
timely
effective
manner,
leading
formation
suppressive
microenvironment.
Establishing
methods
reverse
particularly
important
for
immunotherapy.
Aging
exacerbates
profound
changes
immune
system,
increased
susceptibility
chronic,
infectious,
autoimmune
diseases.
Patients
with
malignant
lung
tumors
have
impaired
function
high
risk
recurrence,
metastasis,
mortality.
Immunotherapy
based
on
PD-1,
PD-L1,
CTLA-4,
other
checkpoints
promising
treating
malignancies.
However,
can
lead
low
efficacy
or
unsuccessful
treatment
results
some
immunotherapies.
Efficiently
blocking
reversing
key
goal
enhancement
This
study
discusses
characteristics,
mechanism,
expression
strategies.
